Pimicotinib in tenosynovial giant cell tumor (TGCT): Efficacy, safety and patient-reported outcomes of Phase 3 MANEUVER study

Niu X, et al. | Oral #11500

Real-world safety and effectiveness of avelumab in immune-compromised (IC) and non-IC patients with Merkel cell carcinoma (MCC): Results from a prospective German registry (MCC-TRIM)

Becker J, et al | Poster #9543

Avelumab + sacituzumab govitecan (SG) vs avelumab monotherapy as first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC): Interim analysis from the JAVELIN Bladder Medley phase 2 trial 

Hoffman-Censits J, et al. Avelumab  | Oral #4501

Avelumab maintenance therapy in patients (pts) with advanced urothelial carcinoma (UC) in Japan: Subgroup analyses by best overall response (BOR) to prior platinum-based chemotherapy (PBC) in a post-marketing surveillance (PMS) population

Kikuchi E, et al | Poster #4561

Comorbidity burden and risk factors (RFs) for peripheral neuropathy (PN) and their prevalence in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Combined results of 2 systematic literature reviews (SLRs) and a meta-analysis 

Kearney M, et al. | e-abstract #e23313

Differences in patient (pt) characteristics and therapy choice across treatment (tx) groups in locally advanced or metastatic urothelial cancer (la/mUC) in the US: A survey on unmet patient needs 

Milloy N, et al.  | e-abstract #e16561

Management and outcomes of rash, peripheral neuropathy (PN), and hyperglycemia (HG) during first-line (1L) treatment (tx) of locally advanced/metastatic urothelial cancer (la/mUC) in a real-world setting 

Nizam A, et al. | e-abstract #e23275

Real-world safety among patients with locally advanced or metastatic urothelial cancer (la/mUC) treated with first-line (1L) systemic regimens: Results from the ELEVATE UC-I study

Nizam A, et al. | e-abstract #e16554

JAVEMACS chart review study of avelumab maintenance in patients with advanced urothelial carcinoma (aUC) in Japan: Analyses of subgroups defined by second-line (2L) treatment

Kobayashi T, et al. | e-abstract #e16550

Population-adjusted indirect comparison (PAIC) of avelumab (AVE) and retifanlimab (RETI) in the first-line (1L) treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC)

Kearney M, et al | e-abstract #e21513

Precemtabart tocentecan (M9140), an anti-CEACAM5 ADC with exatecan payload, in patients with metastatic colorectal cancer (mCRC): Results from the dose optimization of the phase 1 PROCEADE CRC-01 study

Kopetz S, et al | Poster #4561

A phase 1b/2, multicenter study of precemtabart tocentecan (M9140), an anti-CEACAM5 antibody-drug conjugate (ADC) with exatecan payload, in patients with advanced solid tumors

Wainberg Z, et al. | Poster #4561